Atria Wealth Solutions Inc. Lowers Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Atria Wealth Solutions Inc. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,110 shares of the company’s stock after selling 39 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in IDEXX Laboratories were worth $2,836,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Valley National Advisers Inc. grew its holdings in IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the period. OFI Invest Asset Management purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $25,000. Venturi Wealth Management LLC increased its holdings in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after buying an additional 43 shares during the last quarter. Geo Capital Gestora de Recursos Ltd purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth $28,000. Finally, Covestor Ltd boosted its holdings in IDEXX Laboratories by 71.8% in the third quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after acquiring an additional 28 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IDXX. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a research note on Tuesday, January 30th. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Barclays raised their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, The Goldman Sachs Group boosted their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

IDEXX Laboratories Stock Up 2.1 %

NASDAQ:IDXX opened at $499.30 on Monday. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average of $531.02 and a 200-day moving average of $511.63. The firm has a market capitalization of $41.47 billion, a PE ratio of 49.58, a price-to-earnings-growth ratio of 3.85 and a beta of 1.26. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.05 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.14 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 in the last ninety days. Company insiders own 2.18% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.